LONDON - ValiRx Plc, a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialization and partnering, announced in a press release that ValiSeek Limited, the joint venture between ValiRx and Tangent Reprofiling Limited ("Tangent") has received notification of a New Zealand Patent Grant Allowance.

Notification from the New Zealand Patent Office advises that the patent, granted in the US as patent US9072743 on 14th May 2015, has received allowance of grant in New Zealand.  This patent covers both the formulation of VAL401 and its use as a treatment against hormone-related cancers, including lung cancer.

Dr Suzanne Dilly, CEO of ValiSeek Limited, commented: "This is the first non-US patent grant allowance received for the VAL401 project and as such, it provides an international validation of the programme to support world-wide commercialisation".